Medindia

X

Exemestane Can Prevent 65 Percent of Tumors in Post-menopausal Women

by VR Sreeraman on  June 24, 2011 at 7:04 PM Clinical Trials News   - G J E 4
The aromatase inhibitor Exemestane can prevent the breast cancer risk by 65 percent in moderate to high-risk postmenopausal women.

This conclusion has been drawn by a three-year study in 4560 women in the US and Europe.
 Exemestane Can Prevent 65 Percent of Tumors in Post-menopausal Women
Exemestane Can Prevent 65 Percent of Tumors in Post-menopausal Women
Advertisement

Importantly, there were no reports of lethal side effects like those caused by breast cancer drugs tamoxifen and raloxifene.

Advertisement
The team reporting the new results say that the lack of side effects with exemestane could make it far more attractive as a preventative treatment, reports New Scientist.

"Our hope is that our trial results turn up the volume on the debate around breast cancer prevention," says Paul Goss of the Massachusetts General Hospital Cancer Center in Boston, head of the research team.

He said that women might do well to take the drug for five years or so when they reach menopause, an age when the risk of breast cancer rises because of increases in the hormone oestrogen.

The trial results suggest that over three years, for every 94 women taking exemestane, a single case of breast cancer would be prevented.

Source: ANI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All